Grooteclaes M, Vernimmen D, Plaza S, Pasleau F, Hodzic D, Winkler-Gol R
Department of Pathology, University of Liège, Belgium.
Cancer Res. 1999 Jun 1;59(11):2527-31.
The HER2 proto-oncogene product is overexpressed in 30% of breast cancers, and this correlates with poor prognosis. Increased levels of HER2 mRNA in breast cancer cell lines result from increased gene transcription. We report the identification of a new 17-bp-long cis sequence located between positions -506 and -489 from the transcription start site. This sequence is recognized by a trans-activating factor that we tentatively named HER2 transcription factor (HTF). This factor, involved in the increased transcription of the HER2 gene in the BT-474 mammary tumor cells, has a molecular weight of about Mr 50,000. HTF can also bind, but with a lower affinity, to a related cis sequence present in the epidermal growth factor receptor promoter. Interestingly, the HTF binding activity is high in nuclear extracts from several mammary tumor cells overexpressing the HER2 gene.
HER2原癌基因产物在30%的乳腺癌中过度表达,这与预后不良相关。乳腺癌细胞系中HER2 mRNA水平的升高是由于基因转录增加所致。我们报告鉴定出一个新的17bp长的顺式序列,位于转录起始位点-506至-489位之间。该序列被一种反式激活因子识别,我们暂时将其命名为HER2转录因子(HTF)。该因子参与BT-474乳腺肿瘤细胞中HER2基因转录的增加,分子量约为50,000道尔顿。HTF也能以较低亲和力结合表皮生长因子受体启动子中的相关顺式序列。有趣的是,在几种过度表达HER2基因的乳腺肿瘤细胞核提取物中,HTF结合活性较高。